Vaccine Development

Nov 15, 2017
BioPharm International
The use of approved platform technologies can reduce the time and cost required to generate new vaccines.
Nov 15, 2017
BioPharm International
Despite the challenges and high cost of development, vaccine innovation is at an all-time high, as new approaches aim to improve global access.
Nov 15, 2017
BioPharm International
Alternatives to time-consuming, error-prone operations promise to reduce vaccine manufacturing costs and improve facility flexibility.
Nov 15, 2017
BioPharm International
Challenge trials may increase in coming years as new and improved challenge agents better emulate “natural” disease states.
Nov 15, 2017
BioPharm International
This article explores some of the challenges, services, and technologies that go into ensuring that vaccines are properly temperature controlled and maintain product integrity for delivery to patients.
Nov 15, 2017
BioPharm International
The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.
Nov 11, 2017
BioPharm International
This article discusses the potential of using high-productivity membrane chromatography to achieve intensified and flexible virus manufacturing.
Nov 10, 2017
By BioPharm International Editors
The company expects to commercially launch the new vaccine in the US in the first quarter of 2018.
Nov 03, 2017
By BioPharm International Editors
The Human Vaccines Project has created the Universal Influenza Vaccine Initiative, a research program that will aim to understand the human immune system’s role in the development of universal influenza vaccines.
Oct 27, 2017
By BioPharm International Editors
The vaccine is approved for the prevention of shingles in adult patients aged 50 years and older.
native1_300x100
lorem ipsum